Here, we focus on one such targeted agent, the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica), and implications for its use in the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Here, BTK is linked to B-cell chronic lymphocytic leukemia.